OPTIMIZE 5.5 - Optimizing Impella 5.5 Outcomes Through Advanced Data Science

The clinical management of patients experiencing severe cardiogenic shock requires precise, real-time monitoring to optimize hemodynamic support and guide therapeutic transitions. The Impella 5.5 micro-axial flow pump provides left ventricular unloading, generating automated internal continuous parameters that reflect moving cardiac states. This study establishes a retrospective, longitudinal framework that integrates these high-frequency device metrics with corresponding clinical data housed within intensive care unit (ICU) digital health records (DHR). By synthesizing these disparate data streams, this research aims to build an advanced analytical framework to support clinical decisions in the cardiogenic shock landscape.

Signal Validation and Data Preprocessing:

The initial phase of the study validates the physiological fidelity of the continuous data stream. High-frequency digital logs generated by the pump console-specifically the optical placement signal-will undergo time-series alignment with standard physiological waveforms recorded in the ICU, using indwelling arterial line pressure data as the reference standard. This signal validation ensures that the longitudinal parameter data accurately capture mechanical positioning and true left ventricular dynamics prior to entering the downstream modeling pipeline.

Analytical Framework and Modeling Strategy:

Following data integration and signal validation, the consolidated dataset will be leveraged to develop predictive models aimed at distinguishing patient trajectories and forecasting complications. The computational pipeline is divided into two primary analytical pathways:

Endpoint Classification:

An artificial neural network will be developed to evaluate patient trajectories toward distinct clinical endpoints: native heart recovery, escalation to heart replacement therapy, or death. The modeling pipeline incorporates a rigorous framework to ensure generalizability and guard against overfitting. The complete dataset will be partitioned into an 80% development subset and a 20% independent testing subset. The development subset will undergo 5-fold cross-validation to drive comprehensive model architecture optimization, systematically testing structural variations to identify the highest-performing network configuration.

Adverse Event Forecasting:

Separate statistical and machine learning architectures will be constructed to evaluate risk patterns and clinical scenarios associated with severe on-device complications, specifically clinical hemolysis, new-onset arrhythmias, and hemocompatibility-related adverse events (HRAEs). These models focus on identifying early-warning clusters within the high-frequency pump log data to identify sub-clinical changes before manifest physiological degradation occurs.

Through these combined pathways, this observational study seeks to lay the foundational algorithmic groundwork for a real-time clinical decision support tool utilizing objective, automated device analytics to improve safety and personalization in mechanical circulatory support.

• Bias Between the Impella 5.5 Placement Signal and ICU Arterial Line Waveforms [Срок оценки: Continuously through the duration of active Impella 5.5 device support (from device insertion up to explant, estimated average of 5 to 14 days).]
• Correlation Coefficient Between the Impella 5.5 Placement Signal and ICU Arterial Line Waveforms [Срок оценки: Continuously through the duration of active Impella 5.5 device support (from device insertion up to explant, estimated average of 5 to 14 days).]
• Concordance Rate of Directional Trends Between the Impella 5.5 Placement Signal and ICU Arterial Line Waveforms [Срок оценки: Continuously through the duration of active Impella 5.5 device support (from device insertion up to explant, estimated average of 5 to 14 days).]
• Percentage of Participants Exhibiting Specific Device-Support Clinical Endpoints [Срок оценки: Through the duration of hospital stay (estimated average of 30 days).]
• Percentage of Participants Experiencing Device-Related Hemolysis [Срок оценки: From device insertion up to 30 days post-explant or hospital discharge, whichever occurs first.]
• Percentage of Participants Experiencing New-Onset Clinically Significant Arrhythmias [Срок оценки: From device insertion up to 30 days post-explant or hospital discharge, whichever occurs first.]
• Number of Hemocompatibility-Related Adverse Events (HRAEs) Per Participant [Срок оценки: From device insertion up to 30 days post-explant or hospital discharge, whichever occurs first.]